Filing Details

Accession Number:
0001179110-10-011553
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-07-09 13:00:00
Reporting Period:
2010-07-07
Filing Date:
2010-07-09
Accepted Time:
2010-07-09 17:59:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1322734 Advanced Life Sciences Holdings Inc. ADLS Biological Products, (No Disgnostic Substances) (2836) 300296543
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1229826 A Richard Reck 1440 Davey Road
Woodridge IL 60517
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-07-07 1,190,000 $0.04 1,290,000 No 4 P Indirect 1,270,000 By Self as Trustee of Richard A Reck Trust; 20,000 by Self as Trustee of Daniel Reck Trus
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect 1,270,000 By Self as Trustee of Richard A Reck Trust; 20,000 by Self as Trustee of Daniel Reck Trus
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Warrant Acquisiton 2010-07-07 1,190,000 $0.00 1,190,000 $0.04
Units Unit Warrant Acquisiton 2010-07-07 11,900 $0.00 11,900 $4.20
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,190,000 2011-01-07 2015-07-07 No 4 P Indirect
11,900 No 4 P Indirect
Footnotes
  1. On July 7, 2010, Mr. Reck purchased at a price of $4.20 per unti, 11,900 units consisting of, in the aggregate, (i) 1,190,000 shares of the Company's common stock, (ii) warrants to purchsae 1,190,000 shares of common stock at an exercise price of $0.042 per share (the "Stock Warrants") and (iii) warrants to purchase an additional 11, 900 units, with each unit consisting of 100 shares of common stock and 100 Stock Warrants, at an exercise price of $4.20 per additional unit (the "Unit Warrants".
  2. The Stock Warrants may be exercised at any time during the period commening six months after the closing date and ending on the fifth anniversary of the closing date. The Unit Warrants may be exercised at any time during the period commencing on the closing date and ending on the earlier of: (i) the date that is 45 days after the Company's first public announcement that the FDA has accepted the Company's Special Protocol Assessment relating to the additional clinical data needed for regulatory approval in the treatment of community acquired bacterial pneumonia and (ii) December 31, 2010.
  3. Each Unit consists of 100 shares of common stock and 100 Stock Warrants.